Request Demo
Last update 25 Oct 2025
JS-103
Last update 25 Oct 2025
Overview
Basic Info
Drug Type Enzyme |
Synonyms JS 103, JS103 |
Target |
Action modulators |
Mechanism Uric acid modulators(Uric acid modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with JS-103CTR20213167
一项在高尿酸血症伴有痛风患者中评估 JS103 注射液在单剂递增和多次给药静脉输注后耐受性、安全性和药代动力学、药效学特征及免疫原性的随机、双盲、安慰剂对照 I 期临床研究
[Translation] A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the tolerability, safety, pharmacokinetics, pharmacodynamics and immunogenicity of JS103 injection after single-ascending and multiple-dose intravenous infusion in patients with hyperuricemia and gout
100 Clinical Results associated with JS-103
Login to view more data
100 Translational Medicine associated with JS-103
Login to view more data
100 Patents (Medical) associated with JS-103
Login to view more data
1
Literatures (Medical) associated with JS-10301 Sep 2006Journal of bioscience and bioengineeringQ3 · ENGINEERING & TECHNOLOGY
Alteration of substrate specificity of fructosyl-amino acid oxidase from Ulocladium sp. JS-103
Q3 · ENGINEERING & TECHNOLOGY
Article
Author: Shigeyuki Imamura ; Takashi Kawaguchi ; Takuji Kouzuma ; Jun-ichi Sumitani ; Issei Yoshioka ; Shinji Koga ; Maki Fujiwara ; Motoo Arai
We showed by random mutagenesis that one-amino-acid substitution at Arg94 in fructosyl-amino acid oxidase from Ulocladium sp. JS-103 enhanced substrate specificity toward fructosyl valine (FV), a model compound of hemoglobin A(1c). Kinetic analysis showed that the specificity of the R94W mutant enzyme toward FV was 14-fold that of the wild-type enzyme. The mutant enzyme obtained will be useful in developing an enzymatic measurement method for hemoglobin A(1c).
100 Deals associated with JS-103
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metabolic Diseases | Phase 2 | China | 23 Jan 2024 | |
| Hyperuricemia | Phase 1 | China | 07 Dec 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free